Compare GeneDx Holdings Corp (WGS) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GeneDx Holdings Corp vs Yum China Holdings Inc — how do they compare? GeneDx Holdings Corp trades at $67.29 (market cap $2.02B), while Yum China Holdings Inc trades at $42.88 (market cap $14.11B). The key difference: Yum China Holdings Inc is far larger — about 7× GeneDx Holdings Corp's market cap, and Yum China Holdings Inc pays a 2.78% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold GeneDx Holdings Corp for 19 Days and Yum China Holdings Inc for 77 Days on average.
| WGS | YUMC | |
|---|---|---|
Market Cap | $2.02B | $14.11B |
Volume | 734,640 | 2,350,650 |
Sector | Health | Consumer Cyclical |
52-Week High | $167.51 | $57.95 |
52-Week Low | $34.51 | $39.98 |
Typical Hold Time | 19 Days | 77 Days |
Enterprise Value | $2.05B | $15.02B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
YUMC trades at $42.99, up 5.76% today, with a bearish technical signal but strong fundamentals. Recent earnings beats and a 73.68% analyst buy consensus highlight positive momentum. The company completed the Pizza Hut China brand acquisition and expanded its Burger Bar concept, signaling growth initiatives. Cash flow from operations remains robust at $1.47B for 2025, though net cash flow is negative due to financing activities.
The outlook is mixed: solid earnings growth and expansion potential support upside, but technical weakness and competitive pressures pose risks. Investors should weigh the attractive valuation (P/E 15.3) against near-term price volatility and market sentiment headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
